Virologist’s Brewed Kitchen VACCINE

Close-up of a syringe drawing liquid from a vial

A cancer researcher brewed beer in his kitchen that doubled as a vaccine, drank it himself, and shared the recipe for anyone to try—what happens next could upend vaccine science forever.

Story Snapshot

Chris Buck engineered yeast to produce polyomavirus vaccine particles in Lithuanian farmhouse ale, targeting BK virus risks in transplant patients.
He and family tested it without institutional approval, producing antibodies with no reported side effects.
Public recipe on Zenodo sparks ethics debates but promises cheap, needle-free vaccines for global use.
Mouse trials succeeded orally; human proof-of-concept blurs DIY science and regulation lines.

Virologist Engineers Vaccine-Producing Yeast at NCI Labs

Chris Buck, virologist at the National Cancer Institute in Maryland, spent over 15 years developing polyomavirus vaccines. His team identified four human polyomaviruses, including BK virus that reactivates in immunocompromised patients, causing kidney rejection, bladder cancers, and brain complications. They created injectable VP1 protein vaccines tested in animals and licensed in India. Buck shifted to yeast delivery after mouse tests showed promise. NCI labs engineered Saccharomyces cerevisiae to produce virus-like particles. Ethics rules barred self-testing, so Buck founded Gusteau Research Corporation for home experiments.

Buck Brews and Consumes First Batches at Home

In late May 2025, Buck home-brewed the first Lithuanian-style farmhouse ale using the engineered yeast. He drank one pint daily for five days. Seven weeks later, he consumed two booster rounds. His brother Andrew joined as tester and co-author. By December 17, 2025, they posted antibody data and full recipe on Zenodo.org, announced via Buck’s Substack “Viruses Must Die.” Tests showed medically safe antibody levels against BK subtypes II and IV in family and a small group, with no adverse effects reported. Live yeast survived stomach acid, inducing gut immunity.

Mouse Trials Validate Oral Delivery Method

Prior lab tests on mice confirmed the approach. Engineered yeast produced polyomavirus-like particles delivered via nose, skin, and oral routes. Only live yeast in fermented beer—not ground dead yeast—triggered strong antibody responses. Buck replicated oral success multiple times in mice. This bypassed purification and needles, leveraging familiar brewing for low-cost production. Vilnius University collaborators aided yeast engineering. The method targets unmet needs in low-resource areas, where cheap oral vaccines could prevent transplant complications.

Public Release Ignites Controversy and Debate

Early 2026 saw Buck present at World Vaccine Congress in Washington, calling results an “earthquake” for open-access science. Media coverage exploded in February-March 2026. Immunologist Bart Chackerian praised live yeast gut immunity as exciting for other diseases. Critics highlight lacks large human trials, peer review, and controls; antibodies do not guarantee protection, and long-term safety remains unknown. NCI stays uninvolved post-yeast engineering. Self-experiment echoes Barry Marshall’s H. pylori precedent but violates modern ethics.

Buck’s open recipe challenges pharma models by eliminating costly steps, potentially disrupting markets while aiding transplant patients and immunocompromised. Breweries fear branding fallout, yet edible vaccines like chocolate or coffee gain precedent. Common sense favors rapid proof-of-concept over endless bureaucracy, aligning with conservative values of innovation and personal responsibility—provided facts drive replication, not reckless misuse by antivax groups. Ongoing developments track public trials.